🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Hongmei Cui

King University

ORCID: 0000-0002-9307-3019

Also affiliated with Peking University, Lanzhou University

MedicineBiochemistry, Genetics and Molecular BiologyDentistry

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Recent Advances in Elucidating Paclitaxel Resistance Mechanisms in Non-small Cell Lung Cancer and Strategies to Overcome Drug Resistance”.

Recent Advances in Elucidating Paclitaxel Resistance Mechanisms in Non-small Cell Lung Cancer and Strategies to Overcome Drug Resistance

Current Medicinal Chemistry(2020)10.2174/0929867326666191016113631

N/A

0DataRank · unranked

66 citations

Kinsie E. Arnst, Duane D. Miller, Wěi Li, Hongmei Cui

Serum SNTF, a Surrogate Marker of Axonal Injury, Is Prognostic for Lasting Brain Dysfunction in Mild TBI Treated in the Emergency Department

Frontiers in Neurology(2020)10.3389/fneur.2020.00249

N/A

0DataRank · unranked

20 citations

Hongmei Cui, Sandi S. Wewerka, Lydia Hamel, Douglas H. Smith, Michael D. Zwank +1 more

The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma

Frontiers in Pharmacology(2021)10.3389/fphar.2021.637098

N/A

0DataRank · unranked

14 citations

Qinghui Wang, Duane D. Miller, Wěi Li, Hongmei Cui